GLP-1 medications
GLP-1 is a hormone your gut releases after you eat — it tells your brain you're full and helps your body manage blood sugar. GLP-1 medications (semaglutide, tirzepatide, and newer molecules) copy that signal, which is why they're so widely studied for weight management and metabolic health.
The articles below explain how these medications work, what the research actually shows, and what side effects and dosing schedules look like in practice. Promise offers compounded GLP-1 medications by prescription only: a licensed provider reviews every request, and not everyone qualifies.
136 articles on this topic
-
Mounjaro vs Zepbound: Same Drug, Two Labels
Both pens hold tirzepatide and run the same dose ladder. What differs is the use printed on the carton — and that is what your insurer reads.
-
Semaglutide for Children: What STEP Young Means
Semaglutide for children ages 6 to 11 has encouraging new trial results, but the news has not changed who can receive Wegovy under its current label. The evidence is promising, early, and best read with a pediatrician.
-
What Is Semaglutide Used For? A Plain Guide
Semaglutide has different jobs depending on the brand: blood sugar control, heart or kidney risk reduction, long-term weight management, or certain liver disease. Here is the plain list before a first visit.
-
Best Tirzepatide Compounding Pharmacy Checklist
The best choice is a pharmacy you can verify: licensed, tied to a real prescription, clear about sterile preparation, and accountable for the vial after it leaves the building.
-
Tirzepatide Pills Don't Exist. Here's What Does
There is no oral tirzepatide, either as a brand product or a validated compounded pill. Real GLP-1 tablets contain semaglutide or orforglipron, which are different medicines.
-
Zepbound vs Wegovy: Two Drugs, Not Two Brands
They get compared like two versions of one medicine. They are not — different molecules, different makers, and different lists of what each one is cleared to treat.
-
No Shortcut: The Peptide FDA Approval Process
Mimrylo’s August 2026 approval is a useful look at the whole path: permission to begin human studies, three trial phases, a full application, manufacturing review, and a label limited to one use.
-
Retatrutide Lawsuit: It Is Still Investigational
Lilly sued six sellers in August, but the practical answer predates the cases: retatrutide remains investigational and no pharmacy can lawfully compound it for patients.
-
Semaglutide and Heart Health: What Studies Show
Semaglutide has been linked to fewer major cardiovascular events in a specific high-risk group, and to better symptoms in one type of heart failure. The numbers are meaningful, but they do not apply to every heart or every formulation.
-
Semaglutide and Vision: What's Real, What's Rare
Most people never have an eye problem because of semaglutide. Two things do come up, though, and they get mixed together constantly — so here is what each one actually is.
-
Semaglutide for Heart Failure Now Has ESC Support
Europe's 2026 heart-failure guideline now says semaglutide or tirzepatide should be considered for symptomatic patients with obesity and an ejection fraction of at least 45%. The recommendation is about symptoms, walking capacity, and quality of life—not proof that semaglutide prevents death.
-
Tirzepatide Diabetic Retinopathy: Who It's For
The tirzepatide diabetic retinopathy warning landed on both U.S. labels in August 2026. It asks for eye monitoring in people who already have the condition — not a finding that the medicine harms eyes.
-
Tirzepatide Heart Benefits: Who the Label Covers
In August 2026 the brand-name version of tirzepatide gained a new use on its label: lowering the risk of heart attack, stroke and cardiac death in adults with type 2 diabetes. Here is what that covers, and what it doesn't.
-
Tirzepatide vs Ozempic: What You're Comparing
Ozempic is a brand of semaglutide, approved for type 2 diabetes. Tirzepatide is a different molecule with its own brands — so the comparison most people want is between two drugs, not a drug and a label.
-
Compounded Tirzepatide Court Ruling Upholds FDA
The Fifth Circuit left FDA's tirzepatide shortage decision in place. That closes the broad shortage-era compounding route, but it does not erase the narrower rules for an identified patient.
-
GLP-1 Patches: Do They Work?
GLP-1 patches sold online are usually supplement stickers, not semaglutide or tirzepatide. Ordinary patches cannot move these large peptide drugs across intact skin in a predictable dose.
-
Semaglutide and Aging: The New Study Is in Mice
A new Nature study found longer life and better physical function in old female mice given semaglutide. It did not test people, so it cannot tell us that semaglutide slows human aging or adds years to human life.
-
Semaglutide L-Carnitine: What the Additive Means
Some compounders add L-carnitine for its role in fat metabolism. The rationale is real biology, but no human trial shows that mixing it with semaglutide improves weight-loss outcomes.
-
FDA Peptide Warning Letters: What They Mean
FDA’s five August 24 letters targeted the way online sellers presented injectable peptides for people—not peptide molecules as a class. Here’s what changed, what didn’t, and how a prescription route differs.
-
Is Semaglutide a GLP-1? What the Class Means
Yes. Semaglutide is a GLP-1 receptor agonist and an engineered peptide. Those labels describe two different things: the receptor it activates and the structure of the medication.
Page 3 of 7 · 136 articles